Welcome to our dedicated page for Vascular Biogenics Ltd. news (Ticker: vblt), a resource for investors and traders seeking the latest updates and insights on Vascular Biogenics Ltd. stock.
Vascular Biogenics Ltd. (Nasdaq: VBLT), a clinical-stage biotechnology company focused on oncology and immune-inflammatory therapies, provides investors and industry professionals with timely updates through this dedicated news hub. Track essential developments including merger progress with Notable Labs, financial disclosures, and advancements in precision medicine research.
This resource consolidates official announcements, regulatory filings, and strategic updates to serve as a comprehensive reference for stakeholders. Key content areas include corporate restructuring details, clinical trial milestones, and executive commentary on therapeutic pipelines. All materials are sourced directly from company releases to ensure reliability.
Visitors will find updates on transformative initiatives like the integration of VBL Therapeutics' targeted therapies with Notable Labs' predictive platform. The page also features analyses of operational strategies designed to enhance shareholder value through innovative treatment development.
Bookmark this page for streamlined access to verified information about VBLT's evolving position in the biotech sector. Check regularly for critical updates affecting investment considerations and therapeutic advancements in precision oncology.
VBL Therapeutics (Nasdaq: VBLT) has expanded its OVAL Phase 3 study of VB-111, targeting platinum-resistant ovarian cancer, into Europe after enrolling the first patient. The study, involving over 200 participants across the U.S. and Israel, aims to establish VB-111 as a potential new standard of care in a challenging disease area. Interim results indicate a significant response rate of over 58%. The study received favorable recommendations from the Data Safety Monitoring Committee to proceed as planned, with the next review expected in Q1 2021.
VBL Therapeutics (Nasdaq: VBLT) announced that its Chairman, Dr. Bennett Shapiro, CEO Prof. Dror Harats, and other board members have purchased approximately 200,000 shares in open-market transactions between November 24 and December 3, 2020. This insider buying may signal confidence in the company's future prospects. VBL focuses on developing first-in-class treatments for cancer and immune/inflammatory conditions, with its leading candidate, VB-111, currently in a Phase 3 trial for platinum-resistant ovarian cancer.
VBL Therapeutics (Nasdaq: VBLT) announced progress in its OVAL Phase 3 study of VB-111 for platinum-resistant ovarian cancer, reporting a response rate of over 50% among approximately 200 enrolled patients. The company’s financial results for Q3 2020 show revenues of $193,000, up from $79,000 in Q3 2019, with a net loss of $5.8 million compared to $4.9 million the previous year. The cash position is strong, with $37.3 million on hand, expected to sustain operations through Q3 2022. VBL also initiated a Phase 2 study for VB-111 in colorectal cancer and reached alignment with the FDA for VB-601's clinical development.
VBL Therapeutics (Nasdaq: VBLT) announced that Prof. Dror Harats, M.D., CEO, will present a corporate overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 10:30 AM Eastern Time. The presentation format will be a fireside chat with analyst Swayampakula Ramakanth, Ph.D. A webcast will be available for live viewing and an archive of the event will be accessible on VBL's Investor Relations page. VBL Therapeutics specializes in developing innovative cancer treatments, including its lead candidate, ofranergene obadenovec (VB-111), which targets solid tumors.
VBL Therapeutics (Nasdaq: VBLT) will host a conference call on November 16, 2020, at 8:30 am ET to report third-quarter financial results and provide a corporate update. The company focuses on developing first-in-class treatments for cancer, with lead candidate Ofranergene obadenovec (VB-111) targeting solid tumors, currently in a Phase 3 trial for platinum-resistant ovarian cancer. VBL's technologies include gene-therapy and antibody platforms.
VBL Therapeutics (Nasdaq: VBLT) announced that the European Patent Office has granted Patent #3328401 for its anti-MOSPD2 monoclonal antibodies targeting various cancers. MOSPD2 is a protein linked to tumor metastasis, making it a promising target for cancer treatment. The patent protects VBL's innovation until at least July 2036. This milestone supports VBL's broader anti-cancer and inflammatory treatment strategies involving their VB-600 platform, which includes monoclonal antibodies and gene therapies.
VBL Therapeutics (Nasdaq: VBLT) announced the appointment of Marc Kozin as Vice Chairman of the Board, transitioning to Chairman in 2021. Current Chairman Bennett Shapiro will remain on the Board after stepping down. Kozin brings over three decades of biopharmaceutical experience, enhancing the company’s leadership as it advances its Phase 3 anti-cancer therapy, VB-111. Shapiro commended Kozin's qualifications for leading the company in fulfilling its mission to provide novel cancer treatments. VBL specializes in treatments for unmet needs in cancer and immune-related conditions.
VBL Therapeutics (Nasdaq: VBLT) announced the European Patent Office granted Patent #3328408 for its investigational anti-MOSPD2 monoclonal antibodies targeting inflammatory conditions. The patent protects the technology until at least July 2036. VBL has shown ex-vivo activity of these antibodies in multiple sclerosis patients and animal models for various inflammatory diseases. VBL plans to initiate a first-in-human study in the second half of 2021, having reached FDA alignment on the development path.
VBL Therapeutics (Nasdaq: VBLT) presented a corporate overview at the H. C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, highlighting progress in its OVAL pivotal study for VB-111 in ovarian cancer. Over a third of participants are enrolled, and interim analysis shows a high response rate consistent with earlier Phase 2 study results. The company focuses on developing innovative cancer treatments and continues to advance its clinical programs despite potential risks related to COVID-19 and financial sustainability.
VBL Therapeutics (Nasdaq: VBLT) revealed new ex-vivo data from its anti-MOSPD2 monoclonal antibodies for treating multiple sclerosis (MS). Presented at the MS Virtual 2020 conference, the study involved 33 patients, showing a remarkable 97% inhibition of monocyte migration, irrespective of disease severity or treatment. The company's lead candidate, VB-601, is advancing through IND-enabling studies with a first-in-human trial anticipated in the second half of 2021. These findings underscore the potential of VBL's proprietary MOSPD2-targeting approach in MS treatment.
FAQ
What is the market cap of Vascular Biogenics Ltd. (vblt)?
